From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?
© 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL)..
Heart failure and liver disease often coexist because of systemic disorders and diseases that affect both organs as well as complex cardio-hepatic interactions. Heart failure can cause acute or chronic liver injury due to ischaemia and passive venous congestion, respectively. Congestive hepatopathy is frequently observed in patients with congenital heart disease and after the Fontan procedure, but also in older patients with chronic heart failure. As congestive hepatopathy can evolve into cirrhosis and hepatocellular carcinoma, screening for liver injury should be performed in patients with chronic cardiac diseases and after Fontan surgery. Fibrosis starts in the centro-lobular zone and will extend progressively to the portal area. Chronic liver injury can be reversible if heart function improves. However, in the case of terminal heart failure, uncontrolled by medical resources or by assistive device support, the combination of heart and liver transplants must be discussed in patients with chronic advanced liver fibrosis. In this review of the literature, we will focus on congestive hepatopathy and its complications, such as liver fibrosis and hepatocellular carcinoma, with the aim of improving the management and surveillance of patients experiencing these complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
JHEP reports : innovation in hepatology - 3(2021), 2 vom: 19. Apr., Seite 100249 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sessa, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 10.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jhepr.2021.100249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322229472 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322229472 | ||
| 003 | DE-627 | ||
| 005 | 20231225181609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhepr.2021.100249 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322229472 | ||
| 035 | |a (NLM)33665589 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sessa, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). | ||
| 520 | |a Heart failure and liver disease often coexist because of systemic disorders and diseases that affect both organs as well as complex cardio-hepatic interactions. Heart failure can cause acute or chronic liver injury due to ischaemia and passive venous congestion, respectively. Congestive hepatopathy is frequently observed in patients with congenital heart disease and after the Fontan procedure, but also in older patients with chronic heart failure. As congestive hepatopathy can evolve into cirrhosis and hepatocellular carcinoma, screening for liver injury should be performed in patients with chronic cardiac diseases and after Fontan surgery. Fibrosis starts in the centro-lobular zone and will extend progressively to the portal area. Chronic liver injury can be reversible if heart function improves. However, in the case of terminal heart failure, uncontrolled by medical resources or by assistive device support, the combination of heart and liver transplants must be discussed in patients with chronic advanced liver fibrosis. In this review of the literature, we will focus on congestive hepatopathy and its complications, such as liver fibrosis and hepatocellular carcinoma, with the aim of improving the management and surveillance of patients experiencing these complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE, angiotensin-converting enzyme | |
| 650 | 4 | |a AFP, α-fetoprotein | |
| 650 | 4 | |a ALP, alkaline phosphatase | |
| 650 | 4 | |a ALT, alanine aminotransferase | |
| 650 | 4 | |a AST, aspartate amino transferase | |
| 650 | 4 | |a BNP, B-type natriuretic peptide | |
| 650 | 4 | |a Combined heart and liver transplant | |
| 650 | 4 | |a Congestive hepatopathy | |
| 650 | 4 | |a FALD, Fontan-associated liver disease | |
| 650 | 4 | |a FIB-4, Fibrosis-4 index | |
| 650 | 4 | |a Fontan-associated liver disease | |
| 650 | 4 | |a GGT, gamma-glutamyltransferase | |
| 650 | 4 | |a HCC, hepatocellular carcinoma | |
| 650 | 4 | |a INR, international normalised ratio | |
| 650 | 4 | |a MELD, model for end-stage liver disease | |
| 650 | 4 | |a NAFLD, non-alcoholic fatty liver disease | |
| 650 | 4 | |a NFS, NAFLD fibrosis score | |
| 700 | 1 | |a Allaire, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Lebray, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Medmoun, Mourad |e verfasserin |4 aut | |
| 700 | 1 | |a Tiritilli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Iaria, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Cadranel, Jean-François |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JHEP reports : innovation in hepatology |d 2019 |g 3(2021), 2 vom: 19. Apr., Seite 100249 |w (DE-627)NLM306339021 |x 2589-5559 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2021 |g number:2 |g day:19 |g month:04 |g pages:100249 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhepr.2021.100249 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2021 |e 2 |b 19 |c 04 |h 100249 | ||